Isto Biologics acquires TheraCell, adding additional novel products to help patients heal faster.
Hopkinton, MA -- Isto Biologics, a leader in surgical-based, orthobiologic regeneration technologies and cell-based therapies, announced today that it has acquired TheraCell, Inc., a California-based regenerative medicine company. The acquisition will strengthen Isto’s focus on offering extraordinary solutions for surgical and clinical care procedures within spine, orthopedics, and sports medicine.
“We are thrilled to add TheraCell’s unmatched technology to our market leading biologics portfolio,” said Don Brown, CEO of Isto Biologics. “TheraCell has excelled in developing advanced bone integrating, anchoring, and bridging technologies for spinal repair for over a decade including their award winning TheraFuze DBF® Fiber Anchor™ and TheraFuze DBF® Fiber Bag.”
The acquisition will expand Isto Biologics’ growing portfolio of orthopedic grafts and introduce TheraCell’s proprietary and patented TheraFuzeDBF® technology that will become part of Isto Biologics’ Influx™ line.
Bradley Patt, PhD, TheraCell’s Co-Founder and CEO shared, “we are pleased that Isto, a leader in allogeneic spine solutions, has recognized the value and importance of what we have developed and are excited about how their patient-centric,outcomes-focused commercial and clinical teams will rapidly accelerate the surgical adoption of the products and technology that we’ve always been passionate about.”
“Both Isto Biologics and TheraCell have achieved success in developing and introducing innovative, first-of-their-kind product offerings to help patients heal faster,” said Harry Holiday, Chairman of the Board at Isto Biologics and Managing Director at Thompson Street Capital Partners(TSCP). “Adding TheraCell’s product portfolio to Isto’s top-tier sales team will add tremendous value to TheraCell’s place in the market. We anticipate an unparalleled synergy by combining these two great organizations.”